Even though a number of ATR and CHK1 inhibitors have been developed and tested as potential anti-tumor agents, the efforts are mainly focused on tumor types exhibiting high levels of replication stress, such as melanoma, pancreatic cancer, and neuroblastoma [14, 62, 63]. The gene discussed is ATR; the disease is neoplasm.